Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 415.60 INR
Change Today -11.60 / -2.72%
Volume 4.8K
As of 6:14 AM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

jenburkt pharmaceuticals (JBP) Snapshot

Open
425.00
Previous Close
427.20
Day High
428.60
Day Low
410.00
52 Week High
08/5/15 - 542.80
52 Week Low
09/16/14 - 240.05
Market Cap
1.9B
Average Volume 10 Days
5.8K
EPS TTM
20.75
Shares Outstanding
4.6M
EX-Date
08/31/15
P/E TM
20.0x
Dividend
6.30
Dividend Yield
1.52%
Current Stock Chart for JENBURKT PHARMACEUTICALS (JBP)

Related News

No related news articles were found.

jenburkt pharmaceuticals (JBP) Related Businessweek News

No Related Businessweek News Found

jenburkt pharmaceuticals (JBP) Details

Jenburkt Pharmaceuticals Ltd. manufactures and markets pharmaceutical formulations in India and internationally. It offers prescription medicines in various therapeutic areas, such as anthelmintic, anti-arthritic, antibiotics, antidiabetic, anti-hypertensive, anti-inflammory analgesic, anti-malarial, anti-osteoporotic, anti-ulcerants, aphrodisiac, dermatological, gastrointenstinal, hematinics, neuropathy, and protein preparation, as well as anti-cough, cold, and allergy. The company was founded in 1985 and is based in Mumbai, India.

603 Employees
Last Reported Date: 08/12/15
Founded in 1985

jenburkt pharmaceuticals (JBP) Top Compensated Officers

Chairman, Managing Director, Member of Stakeh...
Total Annual Compensation: 8.3M
Chief Financial Officer, Whole Time Director,...
Total Annual Compensation: 2.1M
Compensation as of Fiscal Year 2015.

jenburkt pharmaceuticals (JBP) Key Developments

Jenburkt Pharmaceuticals Ltd. Announces Unaudited Standalone Financial Results for the First Quarter Ended June 30, 2015

Jenburkt Pharmaceuticals Ltd. announced unaudited standalone financial results for the first quarter ended June 30, 2015. For the quarter, the company reported net sales/income from operations (net of excise duty) of INR 218.431 million against INR 192.093 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 31.524 million against INR 21.385 million a year ago. Profit from ordinary activities before tax was INR 36.375 million against INR 20.882 million a year ago. Net profit for the period was INR 25.535 million or INR 5.49 per basic and diluted share before and after extraordinary items against INR 14.882 million or INR 3.20 per basic and diluted share before and after extraordinary items a year ago.

Jenburkt Pharmaceuticals Ltd Appoints Anjali Sunil Dalvi as Additional (Woman) Director

Jenburkt Pharmaceuticals Ltd. has informed that the Board of Directors of the company at its meeting held on July 24, 2015, has appointed Ms. Anjali Sunil Dalvi, as an additional (woman) director on the Board of the company.

Jenburkt Pharmaceuticals Ltd. to Report Q1, 2016 Results on Jul 24, 2015

Jenburkt Pharmaceuticals Ltd. announced that they will report Q1, 2016 results on Jul 24, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JBP:IN 415.60 INR -11.60

JBP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for JBP.
View Industry Companies
 

Industry Analysis

JBP

Industry Average

Valuation JBP Industry Range
Price/Earnings 17.8x
Price/Sales 2.2x
Price/Book 5.7x
Price/Cash Flow 14.2x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JENBURKT PHARMACEUTICALS, please visit www.jenburkt.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.